MenAfriVac® breaks the cold chain barrier!
19 February 2014—A study published online today in the journal Vaccine shows that removing the pioneering vaccine from constant refrigeration is not only safe but could extend vaccination coverage to the remotest regions in sub-Saharan Africa.
A second study published in the Bulletin of the World Health Organization shows that cutting out the cold chain could halve storage and vaccine transportation costs.
MenAfriVac®, which is manufactured by Serum Institute of India Ltd., is the first vaccine allowed to travel outside of the cold chain in Africa. As shown in the above photograph, there are no ice packs in the vaccine box, and a peak threshold indicator tells the vaccinators if the vaccine has reached its limit and needs to be discarded.
See the Press Release
See the Vaccine article
See the Bulletin of the World Health Organization study
Access the WHO modules on the use of MenAfriVac in a controlled temperature chain
Photo: Olivier Ronveaux/WHO